Summary:
A study evaluating the safety and efficacy of Simufilam 100mg tablets in subjects with mild-to-moderate alzheimer's disease. 8 visits over 54 weeks.
Qualified Participants Must:
• Age 50-87
•
No tobacco use the last 3 years
•
BMI 18.5 - 37.5
Qualified Participants May Receive:
$90 for each completed study visit.